CFM
CLDX icon

Catalyst Funds Management’s Celldex Therapeutics CLDX Stock Holding History

Catalyst Funds Management’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-900
Closed -$33.3K – 1344
2024
Q2 		$33.3K Buy
+900
New +$34K 0.01% 529

Other funds holding CLDX

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Catalyst Funds Management's CLDX Position: Q3 2024 in Review

Catalyst Funds Management sold out of Celldex Therapeutics (CLDX) in Q3 2024, closing a stake of 900 shares — an estimated $33.3K sold.

Catalyst Funds Management first reported a position in CLDX in Q2 2024 and held it in 1 quarter. The position peaked at $33.3K in Q2 2024. 176 funds tracked by Wall St. Rank hold CLDX as of Q3 2024.

  • Catalyst Funds Management reported no remaining Celldex Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Catalyst Funds Management sold 900 Celldex Therapeutics shares in Q3 2024, an estimated $33.3K.
  • Catalyst Funds Management first reported a position in Celldex Therapeutics in Q2 2024 and held it in 1 quarter.
  • Catalyst Funds Management's Celldex Therapeutics position peaked at $33.3K in Q2 2024.
  • 176 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q3 2024.

Based on Catalyst Funds Management's 13F filing for Q3 2024, filed 14 Nov 2024.